Humacyte Inc. (HUMA)

Name: Humacyte Inc. (HUMA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Humacyte Inc. (HUMA)

Stock Card

$0.68

$-0.02 (-2.80%)

As on 26-Aug-2026 16:17EDT

Market cap

$178 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Humacyte (HUMA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.67 High: 0.71

52 Week Range

Low: 0.53 High: 2.55

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-5.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

4.3
Debt to Equity

0
Book Value

$--
EPS

$-0.5
Face value

--
Shares outstanding

277,798,105

5 Years Aggregate

CFO

$-352.98 Mln

EBITDA

$-524.57 Mln

Net Profit

$-163.17 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Humacyte (HUMA)	-29.0	9.1	-35.1	-54.6	-42.4	-41.7	--
BSE Sensex^*	-8.3	2.1	2.2	-3.9	6.2	6.8	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 26-Aug-2026 | *As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Humacyte (HUMA)	-81.0	77.0	34.6	-70.9
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Humacyte (HUMA)	0.7	178.4	2.1	-96.7	-4,075.3	-562.9	--	6.0
Arrowhead Pharmaceuticals (ARWR)	89.1	12,304.7	669.5	-320.0	-0.8	-71.1	--	26.4
Cytokinetics Inc (CYTK)	79.2	10,682.6	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	56.1	13,400.0	2,435.9	860.6	31.0	43	17	7.3
Halozyme Therapeutics (HALO)	107.1	12,277.1	1,663.7	413.6	36.3	430	31.2	83.9
Krystal Biotech (KRYS)	359.8	10,258.4	440.5	241.5	33.4	18.7	42.2	7.3
Madrigal Pharmaceuticals (MDGL)	538.9	11,938.8	1,283.9	-325.1	-19.0	-57.7	--	22.9
Medpace Holdings (MEDP)	619.1	17,326.2	2,782.3	491.5	21.1	110.1	36.5	39.4
Praxis Precision MedicinesÂ Inc (PRAX)	377.4	10,496.2	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	151.5	9,985.8	282.0	82.9	-28.6	11.4	147	11.6

Shareholding Pattern

View Details

About Humacyte (HUMA)

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple... therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. Read more

Founder, President, CEO & Director

Dr. Laura E. Niklason M.D., Ph.D.
Founder, President, CEO & Director

Dr. Laura E. Niklason M.D., Ph.D.
Headquarters

Durham, NC
Website

https://www.humacyte.com

FAQs for Humacyte (HUMA)

What is the current share price of Humacyte Inc (HUMA) Today?

The share price of Humacyte Inc (HUMA) is $0.68 (NASDAQ) as of 26-Aug-2026 16:17 EDT. Humacyte Inc (HUMA) has given a return of -42.42% in the last 3 years.

What is the current PB & PE ratio of Humacyte Inc (HUMA)?

Since, TTM earnings of Humacyte Inc (HUMA) is negative, P/E ratio is not available.
The P/B ratio of Humacyte Inc (HUMA) is 6.04 times as on 21-Aug-2026, a 13 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.